The antimalarial effect of iron chelators is attributed to their interaction with a labile iron pool within parasitised erythrocytes, and it was postulated that increased affinity to iron as well as increased lipophilicity may improve antimalarial activity. In the present study we have examined the antimalarial effect of 3-hydroxypyridin-4-ones, a family of bidentate orally effective iron chelators whose lipophilicity may be modified by altering the length of the R2 substituent on the ring nitrogen. A significant dose-related suppression of Plasmodium falciparum cultures was observed with all drugs tested in vitro at concentrations of 5 p"l/L or higher. In contrast, there was a clear segregation of the in vivo effect on P berghei in rats (300 mg/kg/d subcutaneous) into two categories: compounds CP20,38, and 40 failed to suppress
B parum strains resistant to existing antimalarial drugs, malaria remains one of the most important health hazards to the world population. Consequently, ongoing efforts to develop new medications for controlling drug-resistant malaria are of considerble
The iron-chelating agent deferoxamine (DF) was shown to suppress malaria in vitro, and in vivo in a number of species?.' The antimalarial effect of D F involves the chelation of a small chelatable iron pool within the parasitized erythrocytes.' For a number of reasons, DF may not be the ideal iron-chelating agent to suppress the malarial parasite: its rate of penetration into parasitised erythrocytes is very slow'o; its absorption from the gastrointestinal tract is poor; and its half-life in the circulation is short, requiring continuous parenteral administration for optimal effectiveness."
In a recent study of N,N'-bis(o-hydroxybenzyl) ethylenediamine-N,N'-diacetic acid (HBED) and other phenolic and catecholic iron chelators we have postulated that both affinity to iron and increased lipophilicity may contribute to the antimalarial activity of an iron chelator." The present studies were undertaken to explore the antimalarial effects of 3-hydroxypyridin-4-ones, a family of bidentate orally effective iron hel la tors.'^,^^ These compounds have an identical affinity to iron, but their lipophilicity may be modified by increasing or reducing the length of the R, substituent on the ring nitrogen." In the text that follows, we report on the effect of N-alkyl modification on the in vivo and in vitro antimalarial activity of 3-hydroxypyridin-4ones.
MATERIALS AND METHODS
The N-alkyl-3-hydroxypyridin-4-one chelators were synthesized and purified as previously described16 and their purity was confirmed by 'H nuclear magnetic resonance, reverse-phase high performance liquid chromatography (HPLC), and elemental analysis. Deferoxamine B (DF) was supplied as the methanesulfonate salt (Desferal) by Ciba-Geigy Ltd, Basel, Switzerland.
Serum iron and total iron-binding capacity (TIBC) were determined by the International Committee for Standardization in Hematology Iron Panel method." Total nonheme iron was measured by the method of Torrance and Bothwell.18
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In vitro studies. malaria, whereas CP51.94, and 96 had a strong antimalarial effect, similar or better than deferoxamine. There was a close linear correlation between the suppression of peak parasite counts and the reduction in hepatic nonheme iron induced by the various drugs tested (r = .9837). The most lipophilic compounds were also the most effective in suppressing malaria and in depleting hepatic iron stores. These data indicate that 3-hydroxypyrydin-4-ones are able to suppress malaria in vivo and in vitro. Because lipid solubility is an important determinant of antimalarial action, our study provides useful information regarding the selection of orally effective iron-chelating compounds that may be suitable for clinical application as antimalarial agents. In vivo studies. Female Wistar rats of the Hadassah strain weighing 125 to 145 g have been used throughout. Malarial infection was produced by the intraperitoneal injection of a standard inoculum of 3 x lo7 parasites of the ANKA strain of P berghei (donated by Dr M Jarra, Mill Hill, UK). These parasites were maintained in our laboratory by biweekly passage in rats of the same strain. Material for inoculation was prepared by dilution 638 HERSHKO ET AL of freshly drawn blood in sterile normal saline. Parasitemia was estimated by counting 500 cells in stained blood films. Parasite counts in all animals were performed on days 6,8,10, 11, and 13 of infection. The design of these in vivo studies was similar to our previous studies on the antimalarial effects of DF?,'* Rats inoculated with P berghei were treated by subcutaneous injections or gavage every 8 hours of the following iron chelators: DF, CP20, CP38, CP40, CP51, CP94, and CP96 according to the dose schedule indicated. The chemical structure of the various CP compounds is shown in Table 1 . To control for possible spontaneous variations in parasite virulence, each study included its own control group of untreated animals, and all groups described in the various tables and figures were studied simultaneously using the same batch of parasites.
Differences in parasite counts were evaluated by Student's t-test. In some animal studies where parasite counts varied widely a nonparametric (Wilcoxon-rank) test was used to confirm differences at the peak day of infection.
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RESULTS
The effect of in vitro incubation of P falciparum cultures with iron-chelating compounds at concentrations ranging from 5 to 45 p,mol/L is shown in Table 2 . With all compounds tested, there was a significant suppression of parasite counts starting at a concentration of 5 p,mol/L, with maximal effects observed at concentrations of 20 to 45 p,mol/L at 3 days of culture. At comparable molar concentrations of the various compounds studied, only minor differences in the suppression of parasite cultures have been found. Figures 1A and B show the in vivo effect of the same compounds used in rats infected with P berghei. Groups of six animals were inoculated on day 0 and then either left untreated (control) or given 300 mg/kg per day of an iron chelator (DF, CP20, CP38, CP40, CP51, CP94, or CP96) administered subcutaneously in three divided doses at 8-hour intervals for 13 consecutive days. There was no mortality encountered during the 13 days of study. In contrast to the in vitro studies showing a similar antimalarial effect of all compound tested, there was a clear segregation in vivo into two categories: compounds CP20, CP38, and CP40 failed to suppress malaria in rats. In contrast, CP51, CP94, and CP96 had a strong antimalarial effect in vivo similar to or better than DF. Figure 2 shows the peak parasite counts in groups of six animals treated by the six hydroxypyridinones, compared with DF and untreated controls. The mean peak parasite count in untreated controls was 14.7% compared with 12.7% with CP20 (P = .409); 12.0% with CP38 (P = .350); and 14.1% with CP40 (P = .197). In contrast, mean peak parasite counts with CP51, CP94, CP96, and D F were 0.2% (P = .OOl), 2.4% (P = .001), 2.8% (P = .002), and 2.2% (P = .001), respectively. Table 3 shows the effect of iron-chelating therapy on total body weight, liver weight, and iron status. Comparison Table 1 . Ai1 groups consisted of six rats and each line represents a single animal. Parasite counts were performed on days 6,8,10, 11, and 13. iron-chelating therapy was administered in three doses given every 8 hours S.C. 300 mg/kg/d for 13 consecutive days.
of hepatic nonheme iron content shows a sharp distinction between compounds with and without an antimalarial effect. Hepatic iron stores in animals treated by CP20, CP38, and CP40 that were unable to suppress malaria were identical with those in untreated controls. In contrast, there was a sharp reduction in hepatic iron stores in all groups treated with the effective antimalarial compounds CP51, CP94, CP96, and DF. CP51, which was the most effective
For personal use only. on April 16, 2017. by guest www.bloodjournal.org From antimalarial, was also the most effective in reducing hepatic iron stores. Unlike hepatic iron stores, the effect of treatment on serum iron concentrations was marginal, with wide variations in individual animals and no consistent correlation between mean values and antimalarial effect.
Further comparison of the various groups in Table 3 shows that total body weight in untreated controls and in the groups treated with CP20, CP38, and CP40 increased by about 30 to 40 g during the 13 days of study. A similar growth rate was found with DF. However, animals treated with CP51, CP94, and CP96 failed to gain weight and with CP051 there was actually a weight loss of 28 g. Similarly, liver weights in animals treated with CP51, CP94, and CP96 were about 2 g less than in controls or in the groups treated with the ineffective antimalarial compounds. Figure 3 shows the relation between antimalarial effect and hepatic iron stores. There was a close linear correlation (r = .9837) between mean peak parasite counts and hepatic nonheme iron content in the various groups studied.
Because CP51, the most effective antimalarial compound identified in the present study, had an adverse effect on growth rates, it was decided to explore the dose-response relation to reduce toxicity. In contrast to the daily dose of 300 mgkg resulting in a 30-g weight loss, reducing the dose to 150 and 40 mg/kg/d resulted in a weight gain of 11 and 43 g, respectively. However, as shown in Fig 4, this reduction in toxicity was also associated with a marked reduction in antimalarial activity. Table 1 . The linear correlation coefficient r = .9837.
Fig 3. Relation between peak parasite counts and hepatic nonheme iron content determined on day 13. Each point represents the mean of six animals. For description of CP compounds see
In view of the marked antimalarial effect of parenteral CP51, 94, and 96, we wished to examine their effect on parasite counts after oral administration. Figure 5 shows the results of oral treatment with CP94, the compound selected for detailed studies because of its optimal combination of high efficacy and low toxicity. Treatment was administered by gastric gavage at 8-hour intervals at a dose of 300 mgkg/d for 13 consecutive days. There was a significant suppression of parasite counts (P < .001) throughout the entire study by oral treatment with CP94, and mean parasite counts were very similar to those encountered with parenteral treatment. The mean body weight on day 0 and 13 was 136 f 2 g and 164 ~f: 2 g in controls and 135 ~f: 2 g and 135 f 7 g with CP94. The mean liver iron on day 13 was 1,256 If: 243 in controls and 666 2 108 with CP94. There was no drug-related mortality, but three of the CP94 animals were lost because of misplacement of the gavage tube. Thus, the efficacy of oral CP94 judged by antimalarial effect, liver iron depletion, and toxicity was very similar to parenteral treatment at an identical dose.
DISCUSSION
In our previous studies we have shown that iron-chelating therapy with DF or with HBED administered parenterally at 8-hour intervals is capable of suppressing malaria in rats ' .'~ We have also shown that the antimalarial effect of iron chelating therapy is independent of host iron status, as effective doses of D F and HBED did not result in a reduction of transferrin iron saturation or interference with erythropoiesis. Conversely, it was found that D F is able to penetrate infected erythrocytes both in vivo and in vitro, and that it interacts with a labile intracellular iron pool.'
Because the ability of DF to penetrate the RBC membrane is limited, it was postulated that other iron chelators with a higher affinity for iron and/or increased lipid solubility would show improved antimalarial activity. The present studies were undertaken to explore the antimalarial effect of a series of bidentate hydroxypyridinone iron chelators, which have therapeutic potential as oral iron chelators in the clinical management of transfusional iron
The hydroxypyridin-4-ones shown in Table 1 have an identical stability constant for iron(II1) of log f3 36. However, they may be made more or less lipophilic by increasing or reducing the length of the R2 substituent on the ring nitrogen. This change is expressed in the partition coefficient between the lipid and aqueous phases of the free ligand and the iron complex. Increasing lipophilicity is expressed by an increasing value of partition coefficient. Previous studies of hydroxypyridin-4-ones using radioironlabeled hepatocytes have shown that the partition coefficient is critical in determining iron release from liver cell^.'^ Highly hydrophilic ligands had no appreciable effect on iron release. Conversely, iron release increased with increasing lipophilicity, with optimal effects observed when the partition coefficient was close to 1. With a further increase in the partition coefficient the ligands acquire appreciable toxicity. These findings imply that membrane permeability, determined by lipophilicity, is an important factor in determining the ability of an iron chelator to mobilize iron from cells, and that hydrophilic iron chelators, which are largely restricted to the extracellular space, are unable to enhance iron efflux from the hepatocyte.
Of the hydroxypyridin-4-ones investigated in this work, CP40 and CP20 had the lowest partition coefficients. Not surprisingly, these proved to be the least-efficient antimalarial compounds, and the least effective in reducing hepatic iron stores. Increased lipophilicity results in appreciable iron mobilization from cultured hepatocytes in vitr015 as well as from hepatic iron stores in vivo. Both of these effects are apparently associated with improved antimalarial activity. Thus, in line with our previous studies of DF and HBED?'* the in vivo antimalarial effect of CP51, CP94, and CP96 was associated with a marked reduction in hepatic iron stores.
We have shown previously that the antimalarial effect of DF cannot be explained by the induction of a general iron-deficient state in the host? The association of antimalarial effect with hepatic iron depletion is therefore not a cause-and-effect relation, but rather an indirect indicator that a given compound is able to penetrate cells and deplete chelatable iron directly. Indeed, the ability of DF, HBED, and the hydroxypyridin-4-ones to inhibit P falcipamm cultures demonstrates that the antimalarial action of the iron chelators is the result of a direct interaction of these compounds with the parasitized erythrocyte.
Our in vivo studies in rats infected with P berghei have shown a clear distinction between CP51, CP94, and CP96, which had a strong antimalarial action, and CP20, CP38, and CP40, which were unable to suppress malaria. In contrast, all of these compounds were found to be effective in suppressing P falciparum in vitro, thus confirming a previous report by Heppner et al.*' Because DF is a hexadentate chelator, whereas all CP compounds are bidentate chelators, at equal molar concentrations D F binds three times as much iron as the CP compounds. Thus, a concentration of 5 pmol/L D F ( Table 2) is equal to 15 pmoVL of each CP compound. When allowance is given to this threefold difference in iron-binding capacity, the antimalarial effect in vitro of D F and all CP compounds was identical.
The apparent contradiction between the similarity of in vitro antimalarial action and variability of in vivo effect of the various CP compounds is best explained by the difference in the conditions of drug supply. In the present study, in vitro exposure to all CP compounds was uninterrupted and lasted for 3 days. Under these conditions, the rate of For personal use only. on April 16, 2017. by guest www.bloodjournal.org From drug uptake was probably unimportant because sufficient time was available for reaching critical intracellular concentrations even for the less lipophilic compounds. In contrast, with in vivo administration, lipophilicity and other variables affecting the pharmacokinetics of the drug may become the dominant factors determining intracellular concentration and antimalarial effect.
Additional studies were performed to characterize the antimalarial properties of CP51, the most effective iron chelator and antimalarial agent identified in the present series. The results of varying the dose from 40 to 300 mgikdd showed that peak parasitemia was inversely proportional to the dose administered, with complete breakthrough at 40 mg/kg/d. Thus, although reducing the dose of CP51 limited the toxic effects of this compound as manifested in severe weight loss at 300 m&g/d, it also resulted in limited antimalarial action. At present, CP94 and CP96 appear to represent the optimal combination of limited toxicity and effective antimalarial action. As shown in Fig 5, CP94 is able to suppress malaria in vivo after oral administration. To our best knowledge, this is the first demonstration of oral antimalarial activity by an iron chelator.
Our previous studies with DF and HBED have shown that the most likely mechanism of the antimalarial effect of iron chelators is interaction with a vital labile iron pool within the parasitized erythrocyte. The origin of the chelatable iron pool in parasitized erythrocytes is at present unclear. In reticulocytes, the chelatable iron may be derived from the continued uptake of transferrin iron, or the induction of transferrin-receptor synthesis in mature parasitized RBCS.'*,~ It is also possible that some of the chelatable iron originates from the catabolism of intracellular hem~globin.'~ The effectiveness of D F and all other iron chelators studied so far in inhibiting the growth of P falciparum in mature human erythrocytes indicates that the chelatable iron pool of reticulocytes derived from ferritin or transferrin iron uptake is not a prerequisite for the intracellular chelation of iron by these compounds, and support the contention that chelatable iron may be derived from hemoglobin catabolism in parasitized mature erythrocytes.
The direct relation between lipid solubility, facilitating the transit of membranes, and in vivo antimalarial action found in the present study lends support to the concept of direct intracellular iron chelation as the most probable mechanism responsible for the antimalarial effect of iron chelators. However, lipid solubility is only one of several variables that may determine in vivo antimalarial action. Other factors affecting the pharmacokinetics of these compounds should also be considered when evaluating the variability in their in vivo effect. The mechanism responsible for the inhibition of parasite proliferation by intracellular iron chelation is unknown. Ribonucleotide reductase, an iron-containing enzyme that is rate limiting in DNA synthesis has been shown to be inhibited by DFZ5az6 and is a possible target of inhibition by iron chelators within parasitized cells. However, other enzyme systems such as tyrosine hydroxylase as well as enzymes involved in glycolysis and the pentose phosphate shunt may also be inhibited by iron chelation.'
Depriving the parasite of a metabolically important source of iron may represent a novel approach to antimalarial drug development. D F is a relatively ineffective intraerythrocytic chelator, and its poor oral absorption and short half-life in plasma limit its usefulness as an antimalarial drug. The present data indicate that other, orally effective iron chelators may have superior antimalarial activity in vivo, and that a systematic screening of available iron-chelating drugs may result in the identification of potentially useful antimalarial compounds. Because lipid solubility appears to be one of the determinants of antimalarial action, the present study provides useful information regarding the selection of orally effective iron-chelating compounds that may be suitable for clinical application as antimalarial agents.
